Financiado en parte por Biologic Pharmamedical Research
Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions
Cavaleri F, Chattopadhyay S, Palsule V, Kar PK, Chatterjee R
Integrative cancer therapies · 4 citas
Etiquetas de revisión
Vínculos de autores con la industriaFinanciado por la industriaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Biologic Pharmamedical Research
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2024-01-01 · Integr Cancer Ther · vol. 23 · pág. 15347354231223499
- Editorial
- SAGE Publishing
- Citado
- 8 citas · más que el 93% de estudios similares · 4.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 74 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Phytochemicals and Medicinal Plants
- Palabras clave
- Withania somnifera, Cancer, Pharmacology, Carcinogenesis, Biology, Cell cycle, Viability assay, Cancer cell, Cancer research, Cell growth, Apoptosis, Medicine, Traditional medicine, Internal medicine, Biochemistry
- MeSH
- humans, withania, neoplasms, cell transformation, neoplastic, plant extracts, cell survival, withanolides, carcinogenesis
5 autores
- Franco Cavaleri🇮🇳 · autor de correspondenciaCooch Behar Panchanan Barma University
- Sukalpa Chattopadhyay
- Vrushalee Palsule
- Pradip Kumar Kar🇮🇳Cooch Behar Panchanan Barma University
- Ritam Chatterjee🇮🇳Cooch Behar Panchanan Barma University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Ashwagandha (Withania somnifera) has gained worldwide popularity for a multitude of health benefits inclusive of cancer-preventive and curative effects. Despite numerous research data supporting the benefits of this wonder herb, the actual use of ashwagandha for cancer treatment in clinics is limited. The primary reason for this is the inconsistent therapeutic outcome due to highly variable composition and constitution of active ingredients in the plant extract impacting ashwagandha's pharmacology. We investigate here an engineered yield: an ashwagandha extract (Oncowithanib) that has a unique and fixed portion of active ingredients to achieve consistent and effective therapeutic activity. Using the MCF7 cell line, Oncowithanib was studied for its anti-neoplastic efficacy and drug targets associated with cell cycle regulation, translation machinery, and cell survival and apoptosis. Results demonstrate a dose-dependent decline in Oncowithanib-treated MCF7 cell viability and reduced colony-forming ability. Treated cells showed increased cell death as evidenced by enhancement of Caspase 3 enzyme activity and decreased expressions of cell proliferation markers such as Ki67 and Aurora Kinase A. Oncowithanib treatment was also found to be associated with expressional suppression of key cellular kinases such as RSK1, Akt1, and mTOR in MCF7 cells. Our findings indicate that Oncowithanib decreases MCF7 cell survival and propagation, and sheds light on common drug targets that might be good candidates for the development of cancer therapeutics. Further in-depth investigations are required to fully explore the potency and pharmacology of this novel extract. This study also highlights the importance of the standardization of herbal extracts to get consistent therapeutic activity for the disease indication.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.